Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usnoflast (ZYIL1) Phase 2 Proof-of-Concept Study in ALS
NCT05981040Phase 2Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of usnoflast in amyotrophic lateral sclerosis (ALS), sponsored by Zydus Lifesciences Limited. Started Nov 2023; status: completed.
02
Drugs
usnoflast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05981040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981040.